Biologica Technologies to exhibit ProteiOS data at AANS Annual Meeting: 3 insights

Shayna Korol -   Print  |

Biologica Technologies will exhibit clinical data for its ProteiOS growth factor at the American Association of Neurological Surgeons Annual Scientific Meeting in New Orleans.

Here are three things to know.

1. ProteiOS is a novel allograft-derived growth factor which provides several osteoinductive, angiogenic and mitogenic growth factors in a lyophilized powder form.

2. It can be used with any scaffold FDA-approved for use with bone marrow aspirate.

3. ProteiOS growth factor is Biologica's first orthopedic and neurosurgery offering. The company launched ProteiOS in a targeted release in 2017 Q4; it is now available across the U.S.

More articles on biologics:

Infuse gets new FDA indication for lateral, anterior spinal fusions with PEEK implants: 5 things to know

Dr. Domagoj Coric treats 1st patient in DiscGenics' trial to treat degenerative disc disease: 5 insights

4 things to know about Datum Orthobiologics, a newly formed company

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers